Fighting the flu: a brief review on anti-influenza agents.
Sambuddha ChakrabortyAshwini ChauhanPublished in: Biotechnology & genetic engineering reviews (2023)
The influenza virus causes one of the most prevalent and lethal infectious viral diseases of the respiratory system; the disease progression varies from acute self-limiting mild fever to disease chronicity and death. Although both the preventive and treatment measures have been vital in protecting humans against seasonal epidemics or sporadic pandemics, there are several challenges to curb the influenza virus such as limited or poor cross-protection against circulating virus strains, moderate protection in immune-compromised patients, and rapid emergence of resistance. Currently, there are four US-FDA-approved anti-influenza drugs to treat flu infection, viz. Rapivab, Relenza, Tamiflu, and Xofluza. These drugs are classified based on their mode of action against the viral replication cycle with the first three being Neuraminidase inhibitors, and the fourth one targeting the viral polymerase. The emergence of the drug-resistant strains of influenza, however, underscores the need for continuous innovation towards development and discovery of new anti-influenza agents with enhanced antiviral effects, greater safety, and improved tolerability. Here in this review, we highlighted commercially available antiviral agents besides those that are at different stages of development including under clinical trials, with a brief account of their antiviral mechanisms.
Keyphrases
- drug resistant
- sars cov
- clinical trial
- multidrug resistant
- end stage renal disease
- escherichia coli
- acinetobacter baumannii
- ejection fraction
- chronic kidney disease
- newly diagnosed
- small molecule
- randomized controlled trial
- drug induced
- open label
- high throughput
- late onset
- high intensity
- cystic fibrosis
- phase ii
- early onset
- patient reported
- extracorporeal membrane oxygenation
- respiratory failure